Our Locations in Europe. Headquarters Affiliates Plant sites. Dublin. London. Amsterdam. Brussels. Pfaffenhofen. Paris. Altkirch. Vienna. Munich. Zurich. Madrid. Rome. Lisbon. Istanbul. European Production Sites. Altkirch , France. Pfaffenhofen, Germany.
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
Exchange rates: (FY 2008) ¥143.5=€1 / (FY 2009) ¥131.2=€1
These figures do not include out-licensing sales.
Potential blockbuster in cardiovascular care
Antiplatelet agent to prevent atherothrombotic events
Discovered by DAIICHI SANKYO and its Japanese research partner Ube Industries, co-developed and co-promoted with Eli Lilly and Company
European launch sequence started in Spring 2009
Key contributor to company sales over the next years
Leading angiotensin receptor blocker (ARB) with excellent blood pressure lowering efficacy
Launched in 2002 as 7th product in the ARB market, still showing high growth rates
OLMETEC® launched in 58 countries worldwide*, including the majority of European markets
Co-marketing agreements with Menarini Group, Pfizer, Nycomed
OLMETEC PLUS® launched in majority of European countries, launch sequence for additionaldosage comprising 40 milligrams olmesartan startedin Spring 2010
SEVIKAR® launched in several European countriesin 2009
Singel pill combination containing olmesartan, hydrochlorotiazide and amlodipine in approval process
*As of February 2010
Fixed dose combination of olmesartan and amlodipine
Significantly lowers blood pressure and was well tolerated in clinical trials
Effective treatment option: Most hypertensive patients need two or more medications to normalise their blood pressure
Approval for majority of European countries achieved, launch started in January 2009
In the U.S. the combination was already approved in September 2007 under the name of AZOR®, sales have been successful since launch in October 2007
20.7% of net sales
Creating first-in-class, best-in-class, high-value-added products
Head of R&D Division
DAIICHI SANKYO EUROPE GmbH
Percentage of net sales
DAIICHI SANKYO R&D
~ 1,500 people
~ 300 people
DAIICHI SANKYO RD Associe
DAIICHI SANKYO DEVELOPMENT (London)
~ 50 people
DAIICHI SANKYO EUROPE (Munich)
Asia, South & Central America
As of 31 March 2010
DAIICHI SANKYOEUROPE GmbH Munich
130 people(development, pharmaceuticaltechnology)
DAIICHI SANKYODEVELOPMENT LTD.London
U3 Pharma GmbH Martinsried
As of 31 March 2010
DAIICHI SANKYO invents and develops globally leading products
Edoxaban is a direct factor Xa inhibitor and a member of a new class of oral anticoagulants.
It is given once daily and has been investigated in phase II trials in patients undergoing orthopedic surgery and in patients with atrial fibrillation.
It is developed solely by DAIICHI SANKYO as a new treatment for the prevention of both arterial and venous thromboembolism.
Edoxaban is tested in two phase III clinical studies
ENGAGE AF-TIMI 48 with about 16,500 patients focuses on prevention of thromboembolic stroke in atrial fibrillation.
HOKUSAI-VTE with about 7,500 patients focuses on the treatment and recurrence-prevention of venous thromboembolism.
*Only developed in Japan / **Only developed in the US / As of March 2010